Cargando…

Economic Costs of Cardiovascular Diseases in Poland Estimates for 2015–2017 Years

BACKGROUND: Cardiovascular diseases are associated with growing public and private expenditure on healthcare regardless geographic region. Therefore, it is necessary to accurately estimate the overall societal costs—both direct and indirect expenses from the perspective of patients, caregivers and e...

Descripción completa

Detalles Bibliográficos
Autores principales: Mela, Aneta, Rdzanek, Elżbieta, Poniatowski, Łukasz A., Jaroszyński, Janusz, Furtak-Niczyporuk, Marzena, Gałązka-Sobotka, Małgorzata, Olejniczak, Dominik, Niewada, Maciej, Staniszewska, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506040/
https://www.ncbi.nlm.nih.gov/pubmed/33013357
http://dx.doi.org/10.3389/fphar.2020.01231
_version_ 1783584944278208512
author Mela, Aneta
Rdzanek, Elżbieta
Poniatowski, Łukasz A.
Jaroszyński, Janusz
Furtak-Niczyporuk, Marzena
Gałązka-Sobotka, Małgorzata
Olejniczak, Dominik
Niewada, Maciej
Staniszewska, Anna
author_facet Mela, Aneta
Rdzanek, Elżbieta
Poniatowski, Łukasz A.
Jaroszyński, Janusz
Furtak-Niczyporuk, Marzena
Gałązka-Sobotka, Małgorzata
Olejniczak, Dominik
Niewada, Maciej
Staniszewska, Anna
author_sort Mela, Aneta
collection PubMed
description BACKGROUND: Cardiovascular diseases are associated with growing public and private expenditure on healthcare regardless geographic region. Therefore, it is necessary to accurately estimate the overall societal costs—both direct and indirect expenses from the perspective of patients, caregivers and employers. RESEARCH DESIGN: The aim of this paper is to determine the direct and indirect costs related to cardiovascular diseases in Poland from 2015 to 2017. All costs are estimated based on data available in the public domain and obtained from the major Polish institutions. Indirect costs were calculated using a modified human capital approach. RESULTS: The financial burden of cardiovascular diseases in Poland is significant. This study revealed that total costs (direct and indirect) of cardiovascular diseases, for 2015–2017, range from 34.9 bn PLN (8.2 bn EUR) to over 40.9 bn PLN (9.6 bn EUR). Total direct cost and indirect costs were approximately 6.1 bn PLN (1.4 bn EUR) (16%) and 31.3 bn PLN (7.3 bn EUR) (84%), respectively. CONCLUSION: Collectively, the estimated direct and indirect cost of cardiovascular diseases provide a useful input for economic impact assessments of public health programs and health technology analyses.
format Online
Article
Text
id pubmed-7506040
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-75060402020-10-02 Economic Costs of Cardiovascular Diseases in Poland Estimates for 2015–2017 Years Mela, Aneta Rdzanek, Elżbieta Poniatowski, Łukasz A. Jaroszyński, Janusz Furtak-Niczyporuk, Marzena Gałązka-Sobotka, Małgorzata Olejniczak, Dominik Niewada, Maciej Staniszewska, Anna Front Pharmacol Pharmacology BACKGROUND: Cardiovascular diseases are associated with growing public and private expenditure on healthcare regardless geographic region. Therefore, it is necessary to accurately estimate the overall societal costs—both direct and indirect expenses from the perspective of patients, caregivers and employers. RESEARCH DESIGN: The aim of this paper is to determine the direct and indirect costs related to cardiovascular diseases in Poland from 2015 to 2017. All costs are estimated based on data available in the public domain and obtained from the major Polish institutions. Indirect costs were calculated using a modified human capital approach. RESULTS: The financial burden of cardiovascular diseases in Poland is significant. This study revealed that total costs (direct and indirect) of cardiovascular diseases, for 2015–2017, range from 34.9 bn PLN (8.2 bn EUR) to over 40.9 bn PLN (9.6 bn EUR). Total direct cost and indirect costs were approximately 6.1 bn PLN (1.4 bn EUR) (16%) and 31.3 bn PLN (7.3 bn EUR) (84%), respectively. CONCLUSION: Collectively, the estimated direct and indirect cost of cardiovascular diseases provide a useful input for economic impact assessments of public health programs and health technology analyses. Frontiers Media S.A. 2020-09-08 /pmc/articles/PMC7506040/ /pubmed/33013357 http://dx.doi.org/10.3389/fphar.2020.01231 Text en Copyright © 2020 Mela, Rdzanek, Poniatowski, Jaroszyński, Furtak-Niczyporuk, Gałązka-Sobotka, Olejniczak, Niewada and Staniszewska http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Mela, Aneta
Rdzanek, Elżbieta
Poniatowski, Łukasz A.
Jaroszyński, Janusz
Furtak-Niczyporuk, Marzena
Gałązka-Sobotka, Małgorzata
Olejniczak, Dominik
Niewada, Maciej
Staniszewska, Anna
Economic Costs of Cardiovascular Diseases in Poland Estimates for 2015–2017 Years
title Economic Costs of Cardiovascular Diseases in Poland Estimates for 2015–2017 Years
title_full Economic Costs of Cardiovascular Diseases in Poland Estimates for 2015–2017 Years
title_fullStr Economic Costs of Cardiovascular Diseases in Poland Estimates for 2015–2017 Years
title_full_unstemmed Economic Costs of Cardiovascular Diseases in Poland Estimates for 2015–2017 Years
title_short Economic Costs of Cardiovascular Diseases in Poland Estimates for 2015–2017 Years
title_sort economic costs of cardiovascular diseases in poland estimates for 2015–2017 years
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506040/
https://www.ncbi.nlm.nih.gov/pubmed/33013357
http://dx.doi.org/10.3389/fphar.2020.01231
work_keys_str_mv AT melaaneta economiccostsofcardiovasculardiseasesinpolandestimatesfor20152017years
AT rdzanekelzbieta economiccostsofcardiovasculardiseasesinpolandestimatesfor20152017years
AT poniatowskiłukasza economiccostsofcardiovasculardiseasesinpolandestimatesfor20152017years
AT jaroszynskijanusz economiccostsofcardiovasculardiseasesinpolandestimatesfor20152017years
AT furtakniczyporukmarzena economiccostsofcardiovasculardiseasesinpolandestimatesfor20152017years
AT gałazkasobotkamałgorzata economiccostsofcardiovasculardiseasesinpolandestimatesfor20152017years
AT olejniczakdominik economiccostsofcardiovasculardiseasesinpolandestimatesfor20152017years
AT niewadamaciej economiccostsofcardiovasculardiseasesinpolandestimatesfor20152017years
AT staniszewskaanna economiccostsofcardiovasculardiseasesinpolandestimatesfor20152017years